

The Importance of Checking *Leishmania* Promastigotes Viability in the Proteomics Analysis of Secretions

Sekresyonların Proteomiks Analizinde *Leishmania* Promastigotların Canlılıklarının Kontrol Edilmesinin Önemi

Sajad Rashidi¹ , Kurosh Kalantar² , Davood Rostamzadeh³ , Gholamreza Hatam^{4*} 

¹Department of Parasitology and Mycology, Shiraz University of Medical Sciences, Shiraz, Iran

²Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran

³Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

⁴Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Cite this article as: Rashidi S, Kalantar K, Rostamzadeh D, Hatam G. The Importance of Checking *Leishmania* Promastigotes Viability in the Proteomic analysis of Secretions. *Turkiye Parazit Derg* 2018; 42(4): 245-8.

ABSTRACT

Objective: The aim of the present study was to compare the efficacy of checking the viability of *Leishmania* promastigote by flow cytometry using propidium iodide (PI) and microscopic method using trypan blue (TB) before proteomics analysis of the secretions.

Methods: The promastigotes (6×10^9) of *Leishmania infantum* in the exponential growth phase were transferred to serum-free media. Then, the viability of promastigotes was checked and compared with flow cytometry and microscopic method at 0, 2, 3, 4, 5, and 72 h.

Results: Flow cytometry did not show many dead cells at 0 to 4 h, and the viability was approximately 98%. The percentage of the dead promastigotes increased to 8% at 5 h and 17% at 72 h. Meanwhile, the microscopic method using TB did not show any dead cell after 4 and 72 h, and the viability was 100%.

Conclusion: The present study confirms the importance of flow cytometry using PI in checking the viability of *Leishmania* promastigotes, especially before the proteomics analysis of the secretions. It also shows that flow cytometry using PI is more sensitive than microscopic method using TB.

Keywords: Flow cytometry, trypan blue, viability, *Leishmania*, proteomics

Received: 30.12.2018

Accepted: 18.06.2018

ÖZ

Amaç: Bu çalışmanın amacı, sekresyonların proteomik analizinden önce, *Leishmania* promastigotunun canlılığının tripan mavisi (TB) kullanılan mikroskopik yöntem ve propidium iyodid (PI) kullanılan akış sitometrisi ile kontrol edilmesinin etkinliğini karşılaştırmaktır.

Yöntemler: Üstel büyüme fazında *Leishmania infantum* promastigotları (6×10^9) serumuz ortama aktarıldı. Daha sonra promastigotların canlılığı 0, 2, 3, 4, 5 ve 72nci saatlerde akış sitometrisi ve mikroskopik yöntemle kontrol edildi ve karşılaştırıldı.

Bulgular: Akış sitometrisi 0 ila 4 saat arasında çok ölü hücre göstermedi ve canlılık yaklaşık % 98 idi. Ölü promastigotların yüzdesi 5 saatte %8'e ve 72 saatte %17'ye yükseldi. Diğer yandan, TB kullanan mikroskopik yöntemde 4 ve 72 saat sonra herhangi bir ölü hücre gözlenmedi ve canlılık % 100 idi.

Sonuç: Bu çalışma, özellikle sekresyonların proteomik analizinden önce, *Leishmania* promastigotlarının canlılığının kontrol edilmesinde PI kullanılarak uygulanan akış sitometrisinin önemini doğrulamaktadır. Ayrıca PI kullanılan akış sitometrisinin, TB kullanılan mikroskopik yöntemden daha duyarlı olduğunu da göstermektedir.

Anahtar kelimeler: Akış sitometrisi, tripan mavisi, canlılık, *leishmania*, proteomik

Geliş Tarihi: 30.12.2018

Kabul Tarihi: 18.06.2018

The abstract of this article was presented at the 3rd International and the 10th National Congress of Parasitology and Parasitic Diseases of Iran (NICOPA10, no.: HN10104350404).

Bu yazının özeti 3. Uluslararası ve 10. Ulusal İran Parazitoloji ve Paraziter Hastalıklar Kongresi'nde sunulmuştur (NICOPA10, no.: HN10104350404).

Corresponding Author / Sorumlu Yazar: Gholamreza Hatam E.mail: hatamghr@sums.ac.ir

DOI: 10.5152/tpd.2018.5834

©Copyright 2018 Turkish Society for Parasitology - Available online at www.turkiyeparazitolog.org

©Telif hakkı 2018 Türkiye Parazitoloji Derneği - Makale metnine www.turkiyeparazitolog.org web sayfasından ulaşılabilir.

INTRODUCTION

Leishmaniasis is a major parasitic vector-borne disease caused by a family of obligate intracellular dimorphic protozoa of the genus *Leishmania*. The life cycle of *Leishmania* includes extracellular promastigote in sandflies and amastigote stage that presents in mammals within mononuclear phagocyte cells (1, 2). To our knowledge, there is no effective treatment with reduced side effect for leishmaniasis in the literature. Therefore, improving the diagnosis, treatment, and vaccination of leishmaniasis is urgent for the control and prevention of this disease (3, 4).

Nowadays, most studies on *Leishmania* are performed using promastigote as this form is more adaptable in vitro, and the required technology for its cultivation is not tedious and laborious (5). The antigenic targets in secretions of *Leishmania* promastigotes are suitable sources for designing vaccines and diagnosing leishmaniasis since these antigens are considered as stimulants of the immune system (6, 7). Therefore, the preparation of excretory-secretory antigens from live promastigotes (viable cells $\geq 98\%$) is a considerable advantage, especially in the proteomics research on secretions of *Leishmania* parasites.

Proteome refers to a set of proteins that have been encoded by the genome (8) and defined as the analysis of proteins to determine their unique identity, quantity, function, and interaction (9). Evidence also shows that proteomics is practically suitable for the analysis of the proteome of the *Leishmania* genus (10). Recently, researchers have attempted to use this technique to identify immunodominant antigens in *Leishmania* parasites and to introduce new targets for vaccines (11).

The preparation of a high-quality sample is an important issue in the proteomics approaches (12). Therefore, it is very essential to provide a reliable method that can determine the viability of *Leishmania* promastigotes before proteomics analysis of the secretions.

For performing some experimental procedures, checking cell viability is the first step (13). Most of the viability tests are based on the integrity of the cell membranes. Vital dyes, such as trypan blue (TB), can penetrate selectively into the dead cells, but the viable cells do not permit these dyes to penetrate the cells so the live cells remain unstained. Therefore, optical microscopy methods are used to count the number of stained and unstained cells using a Neubauer chamber (14).

One of the major practical assays widely used to check the viability is flow cytometry with propidium iodide (PI) staining (15). The PI function is similar to TB and penetrates the dead cells that produce a complex with DNA (16). The advantages of the PI assay are its high accuracy and the possibility of running many samples in a short time. There are only few studies in the literature that have been conducted to improve the TB exclusion test by making the adaptations with flow cytometry (17).

To the best of our knowledge, few studies have checked the viability of *Leishmania* promastigotes before proteomics analysis of the secretions (18-20). Based on various results in this regard, the aim of the present study was to evaluate and to check the viability of *Leishmania infantum* promastigotes by flow cytometry using PI in comparison to microscopic method using TB.

METHODS

Sample preparation and promastigote culture

L. infantum strain (MCAN/IR/07/Moheb-gh) was provided by the Department of Parasitology and Mycology of Medical Sciences, Shiraz, Iran. *L. infantum* promastigotes were mass cultivated at 25 °C in the Schneider's insect culture media (Sigma Chemical Co., St. Louis, MO, USA) supplemented with 20% (v/v) bovine serum (heat inactivation requires the serum to be at 56 °C for 50 min), 100 U/mL penicillin, and 100 µg/mL streptomycin. Then, 6×10^9 promastigotes were collected in the exponential growth phase (day 3) by centrifugation at $2000 \times g$ for 10 min at 4 °C and washed three times with RPMI-1640 (Shellmax Co., China) serum-free media (21).

Washed promastigotes were transferred to 10 mL RPMI-1640 serum-free media for secretions assay. The number of promastigotes was determined by a Neubauer hemocytometer (22). Then, the viability of promastigotes was indicated at 0, 2, 3, 4, 5, and 72 h by flow cytometry using PI and microscopic method using TB.

Flow cytometry assay using PI

Ten thousand promastigotes in 500 µL of the RPMI-1640 serum-free media were incubated in the presence of 5 µL PI solution (1 mg/mL; Sigma Chemicals Co.) for 5 min at 23-25 °C (19). Suspended promastigotes were run by flow cytometry (BD FACSCalibur®, USA) set to excitation at 493 nm and emission at 636 nm wavelengths. The results were analyzed by the FlowJo software, version 7 (LLC, USA) at 0, 2, 3, 4, 5, and 72 h.

Microscopic method using TB

In the TB exclusion test, 10 µL of TB was added to 10 µL of RPMI-1640 serum-free media containing 10,000 promastigotes, and the viability was immediately determined at 0, 2, 3, 4, 5, and 72 h (23). In PI and TB experiments, the promastigotes that were exposed to methanol were used as a positive control.

Statistical Analysis

Data were expressed as mean \pm SD of at least three independent experiments. The statistical significant difference between the groups was evaluated using the GraphPad software (GraphPad San Diego, CA, USA). The statistical test was evaluated using the one-way analysis of variance. A $p < 0.05$ was considered statistically significant.

RESULTS

In the present study, the results showed that the PI can precisely discriminate dead promastigotes against viable promastigotes. Interestingly, the percent of dead cells using PI was shown to be time dependent. The cell viability using PI was approximately 98% at 0, 2, 3, and 4 h. However, the viability declined to 92% and 83% after 5 and 72 h, respectively (Figures 1a, b).

Furthermore, the same experiment was performed in regard to TB to evaluate the viability. The percent of the viability of promastigotes in respect to TB was not inconsistent with the PI results. Surprisingly, all promastigotes were viable after 5 and 72 h. In the positive control, the dead cells were measured at approximately 98% by flow cytometry using PI (Figures 1a, b) and 100% by microscopic method using TB.




Figure 1. a, b. The results of flow cytometry with PI for checking the viability of *L. infantum* promastigotes at 2, 3, 4, 5, and 72 h and positive control (a) Values are expressed as mean±SD of three independent experiments (b).

DISCUSSION

Some proteomics studies in *Leishmania* parasites present different antigens that could be effective in the development of vaccines, drugs, and diagnosis of leishmaniasis (7, 24-27). Obtaining secretions from the viable cells is pivotal for having a good interpretation of the results of proteomics experiments (28). Since the contamination of secretions with dead parasites leads to some unreliable data, checking the viability is necessary in this regard.

A proteomics research on the secretions of *Leishmania* promastigotes did not use a precise method to check the viability of promastigotes (29). The findings by Cuervo et al. (18) showed that the best time point for collecting secretions is 3 h based on the TB method. However, our findings indicated that the microscopic method using TB cannot detect dead cells at 3 h, and the accuracy of the results will probably be decreased.

In 2015, Kumar et al. (19) detected the immunostimulant antigens in soluble exogenous antigens in *Leishmania donovani* and used

the microscopic method to check the viability of promastigotes. Their findings identified that the appropriate time for the evaluation of viability is approximately 72 h. Although our microscopy results were in accordance with their study, the flow cytometry results showed that 17% of promastigotes are not viable after 72 h. The microscopic method using TB appears to be imprecise and can lead to an overestimation of the live cells, especially in cases in which we intend to check the viability of many cells (30).

Our findings for PI are somehow in line with the study by Braga et al. (20). They used the flow cytometry assay to check the viability of promastigotes within 2–8 h and proposed that the optimum time for collecting the promastigote secretions is 6 h (19).

To our knowledge, few studies have been conducted to improve the TB exclusion test using flow cytometry (17). They suggested that using TB in flow cytometry could also be precise. However, the use of TB in flow cytometry based on the literature is not common. In addition, they did not compare their results with PI.

CONCLUSION

The present study proposes and confirms that flow cytometry using PI staining should be prioritized for checking the viability of promastigotes in the proteomics analysis of *Leishmania* secretions. In addition, our findings proved that the optimum incubation time is 4 h for obtaining secretions without many dead cells.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – S.R., G.H.; Design – S.R., G.H.; Supervision – G.H.; Resources – G.H.; Materials – G.H.; Data Collection and/or Processing – S.R., K.K., D.R., G.H.; Analysis and/or Interpretation S.R., K.K.; Literature Search S.R.; Writing Manuscript – S.R., K.K., G.H.; Critical Review – G.H.

Acknowledgements: We hereby gratefully acknowledge Dr. Jose Maria Alunda Rodriguez for his helpful discussion and comments on the manuscript.

Conflict of Interest: Authors have no conflicts of interest to declare.

Financial Disclosure: This work was supported by Shiraz University of Medical Sciences (Grant No: 94-7597).

Hakem Değerlendirmesi: Dış bağımsız.

Yazar Katkıları: Fikir – S.R., G.H.; Tasarım – S.R., G.H.; Denetleme – G.H.; Kaynaklar – G.H.; Malzemeler – G.H.; Veri Toplanması ve/veya İşlenmesi S.R., K.K., D.R., G.H.; Analiz ve/veya Yorum – S.R., K.K.; Literatür Taraması – S.R.; Yazıyı Yazan – S.R., K.K., G.H.; Eleştirel İnceleme – G.H.

Teşekkür: Dr. Jose Maria Alunda Rodriguez'e makaleye yaptığı tartışma ve yorumlar için minnetle teşekkür ediyoruz.

Çıkar Çatışması: Yazarlar çıkar çatışması bildirmemişlerdir.

Finansal Destek: Bu çalışma Şiraz Üniversitesi tarafından desteklenmiştir (No: 94-7597).

REFERENCES

1. Beyhan YE, Çelebi B, Ergene O, Mungan M. Seroprevalance of Leishmaniasis in Dogs from Hatay and Burdur Provinces of Turkey and Northern Cyprus. *Turkiye Parazitol Derg* 2016; 40: 9-12. [CrossRef]

2. Tlamçani Z, Er-Rami M. The current status of cutaneous leishmaniasis in Morocco. *Turkiye Parazitol Derg* 2014; 38: 5-8. [\[CrossRef\]](#)
3. Alkawahaj A, Larbi E, Al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. *Ann Trop Med Parasitol* 1997; 91: 899-905. [\[CrossRef\]](#)
4. Rasouli M, Hoseini AZ, Kazemi B, Alborzi A, Kiany S. Expression of recombinant heat-shock protein 70 of MCAN/IR/96/LON-49, a tool for diagnosis and future vaccine research. *Iran J Immunol* 2009; 6: 75-86.
5. Mohammadi-Ghalehbin B, Hatam GR, Sarkari B, Mohebal M, Zarei Z, Jaberipour M, et al. A *Leishmania infantum* FML-ELISA for the detection of symptomatic and asymptomatic canine visceral leishmaniasis in an endemic area of Iran. *Iran J Immunol* 2011; 8: 244-50.
6. Gour JK, Kumar V, Singh N, Bajpai S, Pandey HP, Singh RK. Identification of Th1-responsive leishmanial excretory-secretory antigens (LESAs). *Exp Parasitol* 2012; 132: 355-61. [\[CrossRef\]](#)
7. Rashidi S, Kalantar K, Hatam G. Using proteomics as a powerful tool to develop a vaccine against Mediterranean visceral leishmaniasis. *J Parasit Dis* 2018; 42: 162-70. [\[CrossRef\]](#)
8. Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF, et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. *Biotechnol Genet Eng Rev* 1996; 13: 19-50. [\[CrossRef\]](#)
9. Herosimczyk A, Dejeans N, Sayd T, Ozgo M, Skrzypczak W, Mazur A. Plasma proteome analysis: 2D gels and chips. *J Physiol Pharmacol* 2006; 57: 81-93.
10. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. *Lancet* 2005; 366: 1561-77. [\[CrossRef\]](#)
11. Gupta SK, Sisodia BS, Sinha S, Hajela K, Naik S, Shasany AK, et al. Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of *Leishmania donovani* promastigotes. *Proteomics* 2007; 7: 816-23. [\[CrossRef\]](#)
12. Chandramouli K, Qian PY. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. *Hum Genomics Proteomics* 2009; 2009.
13. Lévesque A, Paquet A, Pagé M. Measurement of tumor necrosis factor activity by flow cytometry. *Cytometry* 1995; 20: 181-4. [\[CrossRef\]](#)
14. Tennant JR. Evaluation of the trypan blue technique for determination of cell viability. *Transplantation* 1964; 2: 685-94. [\[CrossRef\]](#)
15. Edidin M. A rapid, quantitative fluorescence assay for cell damage by cytotoxic antibodies. *J Immunol* 1970; 104: 1303-6.
16. Fried J, Perez AG, Clarkson BD. Flow cytofluorometric analysis of cell cycle distributions using propidium iodide. Properties of the method and mathematical analysis of the data. *J Cell Biol* 1976; 71: 172-81. [\[CrossRef\]](#)
17. Avelar-Freitas B, Almeida VG, Pinto MCX, Mourão FAG, Massensini AR, Martins-Filho OA, et al. Trypan blue exclusion assay by flow cytometry. *Braz J Med Biol Res* 2014; 47: 307-15. [\[CrossRef\]](#)
18. Cuervo P, De Jesus JB, Saboia-Vahia L, Mendonça-Lima L, Domont GB, Cupolillo E. Proteomic characterization of the released/secreted proteins of *Leishmania* (Viannia) braziliensis promastigotes. *J Proteomics* 2009; 73: 79-92. [\[CrossRef\]](#)
19. Kumar A, Samant M, Misra P, Khare P, Sundar S, Garg R, et al. Immunostimulatory potential and proteome profiling of *Leishmania donovani* soluble exogenous antigens. *Parasite Immunol* 2015; 37: 368-75. [\[CrossRef\]](#)
20. Braga MS, Neves LX, Campos JM, Roatt BM, Soares RDdOA, Braga SL, et al. Shotgun proteomics to unravel the complexity of the *Leishmania infantum* exoproteome and the relative abundance of its constituents. *Mol Biochem Parasitol* 2014; 195: 43-53. [\[CrossRef\]](#)
21. Rashidi S, Kalantar K, Hatam G. Achievement amastigotes of *Leishmania infantum* and investigation of pathological changes in the tissues of infected golden hamsters. *J Parasit Dis* 2018; 42: 187-95. [\[CrossRef\]](#)
22. Kaneshiro ES, Wyder MA, Wu Y-P, Cushion MT. Reliability of calcein acetoxy methyl ester and ethidium homodimer or propidium iodide for viability assessment of microbes. *J Microbiol Methods* 1993; 17: 1-16. [\[CrossRef\]](#)
23. Louis KS, Siegel AC. Cell viability analysis using trypan blue: manual and automated methods. *Methods Mol Biol* 2011; 740: 7-12. [\[CrossRef\]](#)
24. McNicoll F, Drummelsmith J, Müller M, Madore É, Boilard N, Ouellette M, et al. A combined proteomic and transcriptomic approach to the study of stage differentiation in *Leishmania infantum*. *Proteomics* 2006; 6: 3567-81. [\[CrossRef\]](#)
25. El Fakhry Y, Ouellette M, Papadopoulou B. A proteomic approach to identify developmentally regulated proteins in *Leishmania infantum*. *Proteomics* 2002; 2: 1007-17. [\[CrossRef\]](#)
26. Kumari S, Kumar A, Samant M, Singh N, Dube A. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. *Curr Drug Targets* 2008; 9: 938-47. [\[CrossRef\]](#)
27. Kumari S, Kumar A, Samant M, Sundar S, Singh N, Dube A. Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis. *Proteomics Clin Appl* 2008; 2: 372-86. [\[CrossRef\]](#)
28. Cuervo P, Saboia-Vahia L, Silva-Filho FC, Fernandes O, Cupolillo E, De Jesus J. A zymographic study of metalloprotease activities in extracts and extracellular secretions of *Leishmania* (Viannia) braziliensis strains. *Parasitology* 2006; 132: 177-85. [\[CrossRef\]](#)
29. Silverman JM, Chan SK, Robinson DP, Dwyer DM, Nandan D, Foster LJ, et al. Proteomic analysis of the secretome of *Leishmania donovani*. *Genome Biol* 2008; 9: R35. [\[CrossRef\]](#)
30. Kim JS, Nam MH, An SSA, Lim CS, Hur DS, Chung C, et al. Comparison of the automated fluorescence microscopic viability test with the conventional and flow cytometry methods. *J Clin Lab Anal* 2011; 25: 90-4. [\[CrossRef\]](#)